| Preeti Mehrotra, MD | |
|
22 S Greene St, Medicine/pediatrics, N3e09, Baltimore, MD 21201-1544 | |
| (410) 328-6110 | |
| Not Available |
| Full Name | Preeti Mehrotra |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 15 Years |
| Location | 22 S Greene St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982839734 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 255271 (Massachusetts) | Primary |
| 2080P0208X | Pediatrics - Pediatric Infectious Diseases | 255271 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc | 4486567104 | 1344 |
News Archive
Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.
Patricia Denny and her husband, Jeff, had hoped to one day get an RV and travel the country. Instead, Jeff has been forced into retirement at age 54 by a lung disease caused by the asbestos that's polluted the small town of Libby, Montana, for decades.
New research reveals the mechanism by which an experimental drug can protect the kidneys from sudden damage, called acute kidney injury (AKI). The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), show how the drug may be able to save many lives and cut medical costs related to the condition.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
› Verified 1 days ago
| Entity Name | Atrius Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871639914 PECOS PAC ID: 4789588641 Enrollment ID: O20031121000582 |
News Archive
Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.
Patricia Denny and her husband, Jeff, had hoped to one day get an RV and travel the country. Instead, Jeff has been forced into retirement at age 54 by a lung disease caused by the asbestos that's polluted the small town of Libby, Montana, for decades.
New research reveals the mechanism by which an experimental drug can protect the kidneys from sudden damage, called acute kidney injury (AKI). The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), show how the drug may be able to save many lives and cut medical costs related to the condition.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
› Verified 1 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194765438 PECOS PAC ID: 4486567104 Enrollment ID: O20031204000918 |
News Archive
Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.
Patricia Denny and her husband, Jeff, had hoped to one day get an RV and travel the country. Instead, Jeff has been forced into retirement at age 54 by a lung disease caused by the asbestos that's polluted the small town of Libby, Montana, for decades.
New research reveals the mechanism by which an experimental drug can protect the kidneys from sudden damage, called acute kidney injury (AKI). The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), show how the drug may be able to save many lives and cut medical costs related to the condition.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
› Verified 1 days ago
| Entity Name | Beth Israel Deaconess Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548202641 PECOS PAC ID: 8123936119 Enrollment ID: O20041001000827 |
News Archive
Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.
Patricia Denny and her husband, Jeff, had hoped to one day get an RV and travel the country. Instead, Jeff has been forced into retirement at age 54 by a lung disease caused by the asbestos that's polluted the small town of Libby, Montana, for decades.
New research reveals the mechanism by which an experimental drug can protect the kidneys from sudden damage, called acute kidney injury (AKI). The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), show how the drug may be able to save many lives and cut medical costs related to the condition.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Preeti Mehrotra, MD 110 Francis Street, Lowry Building, Suite Gb, Boston, MA 02215 Ph: () - | Preeti Mehrotra, MD 22 S Greene St, Medicine/pediatrics, N3e09, Baltimore, MD 21201-1544 Ph: (410) 328-6110 |
News Archive
Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed.
Patricia Denny and her husband, Jeff, had hoped to one day get an RV and travel the country. Instead, Jeff has been forced into retirement at age 54 by a lung disease caused by the asbestos that's polluted the small town of Libby, Montana, for decades.
New research reveals the mechanism by which an experimental drug can protect the kidneys from sudden damage, called acute kidney injury (AKI). The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), show how the drug may be able to save many lives and cut medical costs related to the condition.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
› Verified 1 days ago
Dr. Leonard Anang Sowah, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |